Clinical study on the efficacy of low-dose selective serotonin reuptake inhibitor (SSRI) therapy in the treatment of persistent postural-perceptual dizziness (PPPD)

Abstract

The present study aimed to investigate the diseases preceding persistent postural-perceptual dizziness (PPPD) and the efficacy of low-dose selective serotonin reuptake inhibitor (SSRI) therapy in the treatment of PPPD. The Niigata PPPD Questionnaire (NPQ) was used to assess the efficacy of low-dose SSRI (sertraline [12.5 mg]) therapy. We also examined the adverse reactions to low-dose SSRI and the treatment continuation rate. PPPD was preceded by peripheral and central vestibular disease in 69.6% of cases, migraine-related dizziness in 17.4%of cases, orthostatic dysregulation in 11.6% of cases, and unknown conditions in 1.4% of cases. The efficacy rate of low-dose SSRI therapy in the treatment of PPPD was 75.9%. The incidence of adverse reactions was 23.1%, and the treatment continuation rate was 79.2%. The treatment continuation rate and efficacy rate of patients who received low-dose SSRI therapy were similar to those in previous reports with a reduced incidence of adverse reactions. Low-dose SSRI therapy is a promising treatment for PPPD.